Clinical Roundup UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy April 11, 2025Vol.51 No.14
Drugs & Targets FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors April 11, 2025Vol.51 No.14
Conversation with The Cancer Letter Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy April 04, 2025Vol.51 No.13By Paul Goldberg
Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDAMeanwhile, NASEM sounds “SOS” for health infrastructure April 04, 2025Vol.51 No.13By Claire Marie Porter, Paul Goldberg and Jacquelyn Cobb
Conversation with The Cancer Letter Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising recordCurrent record: $507,000. Proceeds to go to LLS as NIH funding is slashed April 04, 2025Vol.51 No.13By Jacquelyn Cobb
Guest Editorial Rathmell: We must put the individual at the center of our approach to ending cancer April 04, 2025Vol.51 No.13By W. Kimryn Rathmell
Sponsored How City of Hope is using AI to improve surgical outcomes April 04, 2025Vol.51 No.13By City of Hope
In Brief Alec Kimmelman announced as next CEO and Dean of NYU Langone Health April 04, 2025Vol.51 No.13
